Supplementary Figure S4 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance

Supplementary Figure S4 shows the weak cancer cell apoptosis triggered by BCL2 inhibitors, and the increased expression of immune checkpoint markers on T cells from BCL2 inhibitor-treated cancer-bearing mice.